Clinical news
{{{Article_Abstract}}}.. MORE
The European Medicines Agency (EMA) has granted approval for dasiglucagon in 2024, providing a new therapeutic option for the treatment of severe hypoglycemia in diabetes patients. Dasiglucagon, a novel rescue therapy, is formulated to rapidly elevate blood glucose levels during severe hypoglycemic episodes, which can lead to confusion, seizures, unconsciousness, and, in extreme cases, death if n.. MORE
Alectinib has indeed been approved by the US FDA for use as adjuvant treatment in patients with ALK-positive non-small cell lung cancer (NSCLC) following tumor resection... MORE
The FDA has approved revumenib (Revuforj) for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year andolder. This menin inhibitor, developed by Syndax Pharmaceuticals, offers atargeted therapy option for this high-risk leukemia subtype... MORE
The FDA has approved revumenib for relapsedor refractory acute leukemia with a KMT2A translocation in patientsaged 1 year and older, offering a targeted therapy for this geneticsubtype... MORE
TheU.S. Food and Drug Administration (FDA) has approved Iloprost injectionas the first treatment specifically for severe frostbite. Marketed under thename Aurlumyn, iloprost is a vasodilator that helps prevent clotting andreduces the risk of finger or toe amputation in adults with severe frostbite... MORE
The FDA has approved imetelstat for adultswith low- to intermediate-1 risk myelodysplastic syndromes (MDS) andtransfusion-dependent anemia requiring ≥4 red blood cell units over 8 weeks. Itis indicated for patients unresponsive, resistant, or ineligible for erythropoiesis-stimulatingagents (ESAs). Imetelstat, a telomerase inhibitor, addresses a c.. MORE
The FDA has approved Rezdiffra for adultswith noncirrhotic non-alcoholic steatohepatitis (NASH) and moderate to advancedliver scarring, to be used alongside diet and exercise... MORE